The issue is not one of scarcity, as the antiviral is widely abundant. Nor is pricing a major barrier, as Paxlovid is cheap or even free for many. Nor even is it an issue of how well it works ...

When it comes to where the new variant has been detected, right now, it’s more common in Europe. Currently, it’s been ...

Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 ...

At this moment, the world has few tools to combat deadly filoviruses, such as Ebola and Marburg viruses. The only approved ...

Atea has struggled to demonstrate bemnifosbuvir’s COVID potential in the past, including in a phase 2 trial back in the midst ...

A new COVID variant, XEC, has arrived just before fall. The new variant has sprouted from the Omicron variant that developed ...

Merck and Ridgeback Biotherapeutics announced on Friday early result that indicate their experimental oral antiviral drug molnupiravir might halve the risk of death or hospitalization from COVID-19.

Gilead said Thursday that its twice-yearly antiviral reduced the risk of HIV infections by 96% compared to an expected rate ...

Assembly Biosciences reported interim results from its Phase 1a study of ABI-5366, a long-acting HSV inhibitor for recurrent ...

Roche Holdings AG (OTC:RHHBY) released positive topline results of the phase 3 CENTERSTONE study of Xofluza (baloxavir ...

You should also consider whether the antiviral Paxlovid could help you—particularly if you’re at high risk for severe disease ...